1 in 4 CBD Edibles Have Inaccurate Labels, Study Shows

Only 25% of CBD edibles contain the labeled amount of CBD.

That's according to the results retrieved from a study conducted by Leafreport and its partner lab, Canalysis.

Moreover, potency tests revealed that 63% of products had more CBD than labeled.

Lital Shafir, Leafreport's head of products, said Thursday that "some discrepancies were expected," considering that "edibles are harder to measure compared to tinctures, capsules, and other products."

However, he emphasized that the "degree of discrepancy shows yet again the importance of researching the brand before buying and checking the third-party lab results for the products they are most interested in."

According to experts' recommendations, cannabinoid levels in cannabis products shouldn't deviate more than 10%, compared to the amount that's advertised. In addition, CBD products should have between 90% to 110% of the claimed CBD amount.

The Israel-based Leafreport tested over 40 edible products, with only ten that had CBD levels within 10% of the advertised amount. The majority of the companies producing CBD products that satisfied the conditions were "newer, smaller brands."

Meantime, mislabeling seems to be a trend, as other categories of cannabis products, including infused beverages, showed some discrepancies as well.

In September, Leafreport disclosed it had tested 22 infused beverages from 20 popular brands, revealing that 54% of the products contained less CBD than claimed.

Related Links

Are CBD Labels Accurate? Too Many Brands Are Misleading Consumers, Studies Show

4 Takeaways From The FDA's CBD Accuracy Report

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisNewsMarketsPress ReleasesCanalysiscannabis industryCBDedibleslabeling requirementsLeafreportmislabelingpotency testsStudytesting
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.